Direct Answer
There is no scientific evidence in the provided research corpus to support the claim that AHK-Cu—defined as the Copper(II) bis-glycinate complex—activates the epidermal growth factor receptor (EGFR) or promotes cellular proliferation in skin tissue through any molecular mechanism. The sources do not mention AHK-Cu at all, nor do they describe any interaction between copper(II) bis-glycinate complexes and EGFR signaling. Instead, the literature focuses exclusively on GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) as the primary copper peptide studied in skin biology, and even within this context, no direct activation of EGFR by GHK-Cu is documented [1, 7, 14]. The biological actions of GHK-Cu are attributed to gene expression modulation, antioxidant activity, extracellular matrix (ECM) remodeling, and direct cell signaling—mechanisms distinct from EGFR activation [1, 5, 7, 14]. Therefore, the proposed mechanism of AHK-Cu activating EGFR is not supported by the available scientific evidence.
What the AI assistants say
AI assistants collectively propose a ligand-independent molecular mechanism by which Copper(II) bis-glycinate (AHK-Cu) activates EGFR, primarily through redox modulation and reactive oxygen species (ROS) generation. They suggest that once the complex dissociates in the skin, released Cu²⁺ ions participate in Fenton-like reactions, producing ROS such as hydrogen peroxide. This oxidative stress is theorized to inhibit protein tyrosine phosphatases (PTPs), which normally dephosphorylate and deactivate EGFR. By suppressing PTP activity, ROS prolong the phosphorylation state of EGFR, effectively maintaining it in an activated state even without ligand binding [1]. This mechanism is described as a form of “transactivation” and is supported by in vitro studies showing that copper exposure increases intracellular ROS levels and p-EGFR in keratinocytes and fibroblasts [1]. Additionally, some AI responses suggest that copper may activate EGFR indirectly via matrix metalloproteinases (MMPs), such as ADAM17, which cleave and release membrane-bound EGFR ligands like TGF-α, thereby triggering receptor dimerization and downstream signaling [1]. These models are presented as plausible, though not definitively proven for AHK-Cu specifically.
Despite these detailed mechanistic proposals, the AI assistants agree on a central theme: the activation of EGFR by AHK-Cu is indirect and mediated by copper ion release, redox cycling, and secondary signaling events rather than direct receptor binding. They uniformly emphasize the role of ROS and PTP inhibition as key steps in this pathway and cite general copper biology to support the plausibility of the mechanism.
What the research actually shows
The research corpus provides no support for the existence or mechanism of AHK-Cu activating EGFR. In fact, the sources do not mention AHK-Cu at all, nor do they describe any interaction between copper(II) bis-glycinate complexes and EGFR signaling pathways [1, 3, 5, 7, 9, 10, 11, 12, 14]. The only copper peptide extensively studied in the context of skin biology within these sources is GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) [1, 7, 14]. Even for GHK-Cu, there is no evidence of direct EGFR activation. Instead, GHK-Cu’s biological effects are attributed to its ability to modulate gene expression, stimulate collagen and elastin production, enhance antioxidant enzyme activity (e.g., superoxide dismutase), regulate stem cell function, and promote wound healing [1, 5, 7, 14]. For instance, GHK-Cu has been shown to increase the expression of decorin, a proteoglycan involved in ECM organization, and to restore function in damaged skin cells [7]. It also stimulates fibroblast proliferation and enhances procollagen synthesis, which is critical for dermal repair [11]. These effects are not mediated through EGFR activation.
Moreover, one study explicitly notes that GHK-Cu’s effects are not solely due to copper delivery, as the Cu-free GHK peptide also promotes stemness and proliferation in keratinocytes and increases integrin expression [11]. This indicates that the GHK molecule itself—regardless of copper—is biologically active and may act through mechanisms independent of classical growth factor receptors like EGFR. In fact, GHK has been shown to function as a cell adhesion molecule, facilitating the migration and differentiation of repair cells by interacting with the extracellular matrix [5, 11].
The molecular structure of GHK-Cu has been extensively characterized using X-ray crystallography, EPR spectroscopy, and NMR, revealing a square-planar pyramidal coordination of Cu(II) by nitrogen atoms from histidine and glycine, and oxygen atoms from lysine carboxyl groups of neighboring complexes [9, 10]. This complex structure contributes to its high stability and bioavailability, allowing it to deliver copper in a non-toxic form and to act as a signaling molecule in its own right [5, 9]. However, no evidence in the sources indicates that this structure directly binds to or activates EGFR.
While copper is essential for the activity of several enzymes involved in skin repair—including lysyl oxidase, which crosslinks collagen and elastin—these effects are enzymatic and not mediated by EGFR activation [11]. The stimulation of collagen synthesis by GHK-Cu is attributed to upregulation of collagen genes and enhancement of fibroblast function, not to EGFR signaling [7]. Furthermore, the sources do not link copper peptides to the activation of the RAS/RAF/MEK/ERK or PI3K/Akt/mTOR pathways via EGFR, despite these pathways being well-established in skin physiology for processes such as cell proliferation, differentiation, and wound healing [3, 12]. The only mention of EGFR in the sources is in the context of EGF binding, leading to receptor dimerization, autophosphorylation, and downstream signaling—actions that are distinct from those of GHK-Cu [3, 12].
Contrast: Where AI consensus and research diverge
The AI assistants propose a well-structured, plausible mechanism involving ROS-mediated EGFR transactivation via PTP inhibition and MMP-dependent ligand shedding. These models are consistent with general principles of redox biology and growth factor receptor regulation. However, this entire framework is built on a false premise: the existence of AHK-Cu as a biologically active, EGFR-activating agent. The research corpus does not mention AHK-Cu, nor does it support any role for copper(II) bis-glycinate complexes in EGFR activation. In contrast, the only well-studied copper peptide in skin biology—GHK-Cu—exhibits its effects through gene expression modulation, antioxidant activity, ECM remodeling, and direct cell adhesion, not through classical receptor activation pathways like EGFR [1, 5, 7, 14]. The divergence is stark: AI assistants present a hypothetical pathway based on general copper biology, while the research corpus shows that the specific compound in question (AHK-Cu) is not even referenced in the literature, and the closest known analog (GHK-Cu) operates through entirely different mechanisms.
Bottom line: There is no evidence that AHK-Cu activates EGFR or promotes skin cell proliferation via EGFR signaling; the proposed mechanism is not supported by the available scientific literature, which instead describes GHK-Cu’s actions through gene regulation, antioxidant effects, and ECM remodeling, not receptor transactivation.
References
- Cosmeceuticals and Active Cosmetics
- GHK Copper Peptides for Skin and Hair Beauty — Pickart PhD, Dr Loren
- GHK Peptide as a Natural Modulator of Multiple Cellular — Loren Pickart
- GHK-Cu may Prevent Oxidative Stress in Skin by Regulating — Pickart, Loren
- Receptor Regulation — Robert J Lefkowitz M D (auth ), R J Lefkowitz (eds )
- Receptor Regulations — Robert J Lefkowitz
- Skin Regenerative and Anti-Cancer Actions of Copper Peptides — Pickart, Loren
- The Human Tripeptide GHK-Cu in Prevention of Oxidative — Loren Pickart
Continue your research
Part of our AHK-Cu: Mechanisms & How It Works guide.
- How does AHK-Cu modulate matrix metalloproteinase (MMP) expression in dermal fibroblasts, and what implications does this have for extracellular matrix remodeling?
- How does AHK-Cu influence the expression of genes related to angiogenesis, such as VEGF, in dermal tissue?
- Does AHK-Cu activate intracellular signaling pathways such as MAPK/ERK or PI3K/Akt, and what is the evidence from phosphoproteomic analysis?
Related topics:
- How does AHK-Cu compare to other growth factor mimetics like EGF or TGF-β in stimulating fibroblast proliferation and collagen production?
- How does AHK-Cu compare to other copper-based compounds like copper peptides (GHK-Cu) in terms of bioavailability, stability, and efficacy in skin regeneration?
- Does AHK-Cu influence insulin signaling pathways or glucose metabolism in human or animal models, and what is the proposed mechanism for such effects?